4-24-2009

Prediction of Sublingual Bioavailability of Buprenorphine in Newborns with Neonatal Abstinence Syndrome—a case study on physiological and developmental changes using NONMEM and SIMCYP

Di Wu
*Thomas Jefferson University*

Walter K. Kraft
*Thomas Jefferson University*

Michelle E. Ehrlick
*Thomas Jefferson University*

Jeffrey S. Barnett
*University of Pennsylvania*

Follow this and additional works at: https://jdc.jefferson.edu/petfp

Part of the Medical Pharmacology Commons, and the Pharmacy and Pharmaceutical Sciences Commons

Let us know how access to this document benefits you

Recommended Citation


https://jdc.jefferson.edu/petfp/24

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
ABSTRACT

Background: About 55 to 94% of infants born to opioid-dependent mothers have neonatal abstinence syndrome (NAS). Buprenorphine (BUP) is used clinically as an analgesic and as a detoxification agent and as a maintenance treatment for opioid dependence. However, no data, however, has been reported about the use of sublingual administration of BUP below the age of 4 years, especially for term infants with NAS.

Objectives: Characterize pharmacokinetics (PK) of BUP in newborn patients; Evaluate the developmental changes in newborns in order to assist dosing optimization in ongoing clinical studies.

Methods: In silico prediction of PK behavior and physiological development in newborn patients were evaluated using SIMCYP. Intravenous clearance was predicted through physiologically based simulation method in SIMCYP. Based on sublingual clearance obtained from a one compartmental model developed previously using NONMEM, individual changes of sublingual bioavailability were evaluated with physiological development in the first one and half month during the newborn period.

Results: Individual clearance of BUP in newborns were incorporated into enzyme kinetic data obtained from literature. Change of sublingual bioavailability for newborns was evaluated with bioavailability-postmenstrual age profiles. Sublingual bioavailability of BUP was estimated as 8.9–56.6% in newborn patients studied during the first one and half postnatal month.

Conclusion: Developmental considerations for the PK of BUP in newborns are important for the characterization of the dose-exposure relationship. We have evaluated this from “bottom-up” and “top-down” approaches with SIMCYP and NONMEM respectively and found these approaches to be complementary and valuable for clinical trial design and routine clinical care. Presumably they would facilitate rational decision making in pediatric drug development as well.

INTRODUCTION

BUP is a semi-synthetic opioid derived from thebaine and used in clinics as an analgesic and as a detoxification agent and as a maintenance treatment for opioid dependence.

BUP is administered via intravenous and sublingual routes, since BUP has very low oral bioavailability due to extensive first-pass metabolism.

BUP has large volume of distribution and is extensively metabolized to norbuprenorphine (NBUP) by N-dealkylation mediated mainly by CYP3A4 (65%) and CYP2C18 (35%).

BUP is metabolized in other metabolic pathways to a minor extent by CYP 2C9, and 2C19 and to a major extent by CYP 3A.

NAS occurs in 55 to 94% of infants who are born to opioid-dependent mothers. No data has been reported about the use of sublingual administration below the age of 4 year, especially for term infants with NAS. Therefore, there is a great need to determine the PK characteristics to optimize pediatric therapy.

MODEL DEVELOPMENT

Nonlinear mixed-effect modeling was employed to characterize the pharmacokinetics of BUP and NBUP based on data from a pilot clinical trial in 12 newborn patients with NAS (Pediatrics, 2008, 122, 661-607).

Population PK analysis was performed using NONMEM software, Version VI, Level 1.1.

One compartment model with first order absorption, metabolism, and elimination was described in describing the PK of BUP and NBUP.

OBJECTIVES

1. To characterize PK and sublingual bioavailability of buprenorphine (BUP) in target population during newborn period.
2. To evaluate the developmental changes in newborns in order to assist dosing optimization in ongoing clinical studies.

MODEL DESCRIPTION

Table 1 Summary of demographic characteristics for newborns (N = 12) at baseline

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean (SD)</th>
<th>Median (min, max)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td>2.76 (0.39)</td>
<td>2.52 (2.25, 3.02)</td>
</tr>
<tr>
<td>Length (cm)</td>
<td>48.3 (2.2)</td>
<td>47.5 (45, 50)</td>
</tr>
<tr>
<td>GA (weeks)</td>
<td>37.3 (1.5)</td>
<td>37 (36, 38)</td>
</tr>
<tr>
<td>Gestational Age (GA)</td>
<td>36.2 (1.1)</td>
<td>36 (34, 38)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>1547 (230)</td>
<td>1513 (1300, 1600)</td>
</tr>
<tr>
<td>Gestational age (GA)</td>
<td>36.2 (1.1)</td>
<td>36 (34, 38)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>2.76 (0.39)</td>
<td>2.52 (2.25, 3.02)</td>
</tr>
<tr>
<td>Length (cm)</td>
<td>48.3 (2.2)</td>
<td>47.5 (45, 50)</td>
</tr>
</tbody>
</table>

Sublingual bioavailability of ID 13, 22, and 27 showed less linear increase with PMA, compared with that of all other newborns. It might be due to large percentage of NBUP dose not being administered (medical record errors) and/or analytical measurement errors.

Large individual variability has been observed in sublingual bioavailability. Higher values of bioavailability observed might be due to underestimated Cl,.... and/or overestimated V,....

Sublingual bioavailability was estimated from 13.5% to 56.6% in the 9 neonates treated exclusively with BUP during the first one and half postnatal month.

SIMULATION with SIMCYP

In vitro enzyme kinetic data was incorporated into SIMCYP to simulate intravenous clearance in newborn patients. In vitro enzyme kinetic data obtained from literature. Change of sublingual bioavailability for newborns was evaluated with bioavailability-postmenstrual age profiles. Sublingual bioavailability of BUP was estimated as 8.9–56.6% in newborn patients studied during the first one and half postnatal month.

Table 2 Treatment information

<table>
<thead>
<tr>
<th>Treatment Information</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUP</td>
<td>10 (83.3%)</td>
</tr>
<tr>
<td>NBUP</td>
<td>2 (16.7%)</td>
</tr>
</tbody>
</table>

Growth factors such as age, body weight can be important covariates to BUP exposure levels in newborns, given the fact of the significant changes of body fat content and enzyme levels of CYP 3A, 2C9, 2C19 and 2C19.

Dose adjustment is needed for BUP therapy in newborns based on lower sublingual bioavailability estimated in newborn patients, compared to that of BUP sublingual bioavailability observed in adults, and drug-drug interaction induced by phenobarbital. A larger, double-blind, properly powered clinical trial on BUP in young infants will enhance and validate this model.

RESULTS

CONCLUSIONS

The population pharmacokinetic model is based on data from 12 newborn patients with NAS. Three newborn patients (D13, 22, & 27) were co-treated with phenobarbital during certain period of treatment.

Simulations of intravenous clearance of BUP was conducted in 12 newborn patients with NAS.

In vitro enzyme kinetic data was incorporated into SIMCYP to simulate intravenous clearance in newborn patients.

Molecular weights, pk, log P, *dose*

• unbound fraction in plasma (*C*)
• average renal clearance in adult
• bound to plasma ratio

V, K values derived using human liver microsomes (recombinant CYPs)

• unbound fraction in human liver microsomes (recombinant CYPs)

Sublingual bioavailability was estimated by comparing intravenous clearance (CL,iv) obtained from SIMCYP simulation to sublingual clearance (CL,sub) generated using non-linear mixed effect modeling with NONMEM.

Sublingual bioavailability—PMA profiles were drawn from the time they were born till BUP treatment completed for each of the 12 newborn patients.

ACKNOWLEDGMENT

We cordially thank Dr. Measre Jannke and Steve Marrison in Simcyp Limited for their technical assistance to operation and installation of SIMCYP software.